Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Clinical diagnosis of Systemic Lupus Erythematosus (SLE) confirmed by Systemic Lupus International Collaborating Clinics (SLICC) classification criteria
Moderate to severe SLE disease activity
Evidence for at least 1 of the following SLE markers:
The subject is receiving stable SLE standard-of-care medication
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
182 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal